|
News GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair in COPD and asthma
GlaxoSmithKline and Theravance, Inc. announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair |
|
News GlaxoSmithKline commences Relovair Phase III asthma programme
Issued: Friday 19 March 2010, London UK. GlaxoSmithKline (GSK) announced today that the first asthma patient has commenced treatment with Relovair™ (fluticasone furoate/vilanterol trifenatate) in an asthma exacerbation study, marking the start of the Phase III clinical development programme with this once daily therapy, for this serious and chronic disease. |